Leadership team
Pheon has a very strong leadership team of specialists, bringing together the best of clinical and managerial expertise with a proven track record in targeted oncology therapies and ADCs.
Chung-Han Lee, MD, PhD
Vice President, Clinical Development
Dr. Chung-Han (Joe) Lee brings over a decade of experience to his role as Vice President, Clinical Development at Pheon Therapeutics. He has successfully led numerous early and late-phase clinical trials and overseen the development of early-phase assets across diverse mechanisms of action.
Prior to joining Pheon, Dr. Lee served as VP of Early Clinical Development at Exelixis, where he managed a portfolio of ADCs, novel immunotherapies, and small molecules from drug candidate nomination to proof of developability.
In academia, Dr. Lee was an internationally recognized expert in renal cell carcinoma at Memorial Sloan Kettering Cancer Center. He led early-phase trials for multiple VEGF-targeted TKI combinations, resulting in three NCCN compendium designations. He also designed and implemented an IST that led to an NCCN preferred designation for non-clear cell kidney cancer, securing external funding from the Department of Defense and other foundations for translational research. Dr. Lee has authored over a hundred abstracts and publications, and been an invited speaker both nationally and internationally.
Dr. Lee earned his MD/PhD from the University of Michigan and completed his residency in internal medicine at New York Presbyterian – Weill Cornell, followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center.
